NEOS Investment Management LLC Has $894,000 Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)

NEOS Investment Management LLC lowered its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) by 25.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,150 shares of the company’s stock after selling 10,929 shares during the period. NEOS Investment Management LLC’s holdings in Akero Therapeutics were worth $894,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AKRO. Victory Capital Management Inc. acquired a new position in shares of Akero Therapeutics during the 3rd quarter worth about $211,000. AlphaQuest LLC boosted its position in Akero Therapeutics by 32,588.0% during the fourth quarter. AlphaQuest LLC now owns 8,172 shares of the company’s stock valued at $227,000 after purchasing an additional 8,147 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Akero Therapeutics in the third quarter valued at approximately $265,000. XTX Topco Ltd acquired a new position in shares of Akero Therapeutics during the 3rd quarter worth approximately $308,000. Finally, Sei Investments Co. bought a new stake in shares of Akero Therapeutics during the 4th quarter worth approximately $303,000.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Canaccord Genuity Group raised their target price on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $35.00 to $63.00 in a research note on Thursday, January 30th. Citigroup raised their target price on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. HC Wainwright lifted their price target on Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Monday, March 3rd. Finally, UBS Group upped their price objective on Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $76.29.

Insiders Place Their Bets

In other Akero Therapeutics news, VP Patrick Lamy sold 5,000 shares of the stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $57.03, for a total transaction of $285,150.00. Following the transaction, the vice president now owns 33,492 shares in the company, valued at $1,910,048.76. This represents a 12.99 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Andrew Cheng sold 30,000 shares of Akero Therapeutics stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $54.90, for a total transaction of $1,647,000.00. Following the completion of the sale, the chief executive officer now owns 716,062 shares of the company’s stock, valued at approximately $39,311,803.80. The trade was a 4.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 341,309 shares of company stock worth $15,863,578 and have sold 252,135 shares worth $12,345,079. Company insiders own 7.94% of the company’s stock.

Akero Therapeutics Stock Down 2.0 %

Shares of AKRO opened at $42.72 on Monday. The firm has a market cap of $3.40 billion, a P/E ratio of -11.39 and a beta of -0.19. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. Akero Therapeutics, Inc. has a 52 week low of $17.86 and a 52 week high of $58.40. The firm’s 50-day simple moving average is $46.01 and its 200 day simple moving average is $35.15.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.01). On average, analysts forecast that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.